Live feed08:00:00·130dPRReleasevia QuantisnowArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung CancerByQuantisnow·Wall Street's wire, on your screen.AVBP· ArriVent BioPharma Inc.Health Care
